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Superenhancers (SEs) are large genomic regions with a high density of enhancermarks. In cancer, SEs are found near
oncogenes anddictate cancer gene expression.However, howoncogenic SEs are regulated remains poorlyunderstood.
Here,weshowthat INO80, achromatin remodeling complex, is required for SE-mediatedoncogenic transcriptionand
tumor growth inmelanoma.Theexpressionof Ino80, theSWI/SNFATPase, is elevated inmelanomacells andpatient
melanomas compared with normal melanocytes and benign nevi. Furthermore, Ino80 silencing selectively inhibits
melanoma cell proliferation, anchorage-independent growth, tumorigenesis, and tumor maintenance in mouse xe-
nografts.Mechanistically, Ino80 occupies >90%of SEs, and its occupancy is dependent on transcription factors such
as MITF and Sox9. Ino80 binding reduces nucleosome occupancy and facilitates Mediator recruitment, thus pro-
moting oncogenic transcription. Consistently, genes co-occupied by Ino80 andMed1 are selectively expressed in
melanomas compared with melanocytes. Together, our results reveal an essential role of INO80-dependent chro-
matin remodeling in SE function and suggest a novel strategy for disrupting SEs in cancer treatment.
[Keywords: INO80; chromatin remodeler; oncogenic transcription; superenhancer]
Supplemental material is available for this article.
Received December 31, 2015; revised version accepted May 23, 2016.
Genomic regulatory elements have become increasingly
important in understanding the molecular foundations
of cancer and developing potential strategies for cancer
therapies (Mansour et al. 2014; Weinhold et al. 2014; Mel-
ton et al. 2015). Among them, superenhancers (SEs) are ge-
nomic regions with an unusually high density of enhancer
markers such as H3K27 acetylation (H3K27ac) and the
Mediator complex (Heinz et al. 2015; Pott and Lieb
2015). Representing a small fraction of all enhancers,
SEs are critically involved in the expression of cell type-
specific genes important for development and disease
(Chapuy et al. 2013; Hnisz et al. 2013; Loven et al. 2013;
Whyte et al. 2013; Chipumuro et al. 2014; Kwiatkowski
et al. 2014). In cancer, SEs are enriched at genes with
known oncogenic function, and genomic rearrangements
often encompass SEs (Affer et al. 2014; Groschel et al.
2014; Northcott et al. 2014; Walker et al. 2014). However,
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how SEs are regulated and maintained in cancer remains
to be elucidated.
Melanoma is among the most common cancers in the
United States. Activation of the MAPK pathway, such
as bymutations in BRAForNRAS, is found in themajority
of patients. In addition, recent studies have revealed a
complex involvement of epigenetic mechanisms in mela-
noma development and progression. Particularly, factors
involved in chromatin regulation, such as the chromatin
remodeling complexes,were found to play important roles
in controlling the gene expression program in melanoma
(van den Hurk et al. 2012; Mehrotra et al. 2014). The ATP-
dependent chromatin remodelers are capable of remodel-
ing chromatin structure by sliding, ejecting, or exchang-
ing nucleosomes and are therefore critically engaged in
chromatin organization, accessibility, and gene regulation
(Ho and Crabtree 2010; Piatti et al. 2011). Although chro-
matin remodelers areoften found tobemutated in cancers,
including melanoma (Roberts and Orkin 2004; Mayes
et al. 2014; The Cancer Genome Atlas Network 2015),
themechanisms bywhich they contribute to carcinogene-
sis and tumor maintenance are not fully understood.
INO80 belongs to the INO80 subfamily of the chroma-
tin remodeling complexes (Morrison and Shen 2009;
Watanabe and Peterson 2010). It has been implicated in
many crucial cellular functions, including transcription
regulation, DNA replication and repair, telomere mainte-
nance, and chromosome segregation. Deletion of Ino80,
the SWI/SNF ATPase in the complex, resulted in early
embryonic lethality (Min et al. 2013). In addition, Ino80
depletion inhibited cell proliferation and anchorage-inde-
pendent growth. Interestingly, INO80 haploinsufficiency
had no impact on tumor incidence and latency in p53-null
mice. Instead, it altered the tumor spectrumand increased
the percentage of invasive sarcomas (Min et al. 2013). De-
spite these findings, the involvement of INO80 in cancer
is still much less well characterized compared with the
SWI/SNF chromatin remodelers (Masliah-Planchon
et al. 2015).
Recently, INO80 has been found to selectively activate
pluripotency genes in embryonic stem cells (ESCs) by
maintaining an open chromatin structure at promoter-
proximal enhancers (Wang et al. 2014). As genes and path-
ways important for ESCmaintenance are often reactivated
in cancer (Kim and Orkin 2011), we set out to investigate
whether and how INO80 may be involved in tumorigene-
sis. Here, we show that INO80 indeed plays an essential
role in melanoma proliferation and tumorigenesis. It
occupies SEs and promotes oncogenic transcription by fa-
cilitating nucleosome depletion and Mediator recruit-
ment. Our data define a critical role of INO80-mediated
chromatin remodeling in cancer development and the reg-
ulation of SEs.
Results
Ino80 is highly expressed in melanoma
To test the role of INO80 in melanoma and oncogenic SE
regulation, we examined the expression of its subunits
during melanoma progression. Based on data published
by The Cancer Genome Atlas Network (2015), several
INO80 subunits show elevated mRNA levels in metastat-
ic melanoma compared with primary melanoma (Supple-
mental Fig. S1A), and elevated expression was associated
with poor prognosis (Supplemental Fig. S1B). In addition,
we found that the protein level of Ino80, the core SWI/
SNF ATPase of the complex, was also increased in prima-
ry melanomas compared with benign nevi in patient sam-
ples, as determined by immunohistochemical staining
with a validated antibody (Supplemental Fig. S1C; Wang
et al. 2014). Finally, we found that Ino80 protein levels
were higher in melanoma cell lines harboring BRAF or
NRASmutations, themost frequent oncogenicmutations
found in melanoma, compared with primary normal me-
lanocytes (Fig. 1A). Consistent with these results, chro-
matin immunoprecipitation (ChIP) followed by high
through-put sequencing (ChIP-seq) showed prominent
peaks of enhancer markers such as H3K27ac, H3K4me1,
and Med1 as well as RNA polymerase II (Pol II) near the
Ino80 transcription start site (TSS) in melanoma cells
(Supplemental Fig. S1D), indicative of active transcription
of the Ino80 gene. Together, these observations demon-
strated a clear correlation between Ino80 expression and
melanoma progression.
Intriguingly, treatment of BRAFmutant melanoma cell
lines with either of two commonly used FDA-approved
anti-melanoma drugs—the BRAF inhibitor vemurafenib
or the MEK inhibitor trametinib—led to a reduction in
Ino80 protein levels (Fig. 1B). In contrast, vemurafenib
treatment had no effect on cells that are resistant to the
drug (Fig. 1B,C). Thus, Ino80 expression appears to be high-
ly sensitive to the inhibitionof upstreamdrivermutations.
To understand how the driver kinases regulate Ino80, we
first examined Ino80 mRNA expression after trametinib
treatment. Surprisingly,MEK inhibition resulted in slight-
ly elevated levels of Ino80mRNA (Fig. 1D), suggesting that
the MAPK pathway may regulate Ino80 post-translation-
ally. To test the hypothesis,we inhibited protein synthesis
with cycloheximide and examined the Ino80 protein level.
Indeed, we found that trametinib treatment enhanced the
degradation of the Ino80 protein (Fig. 1E). Interestingly,
trametinib affected Ino80 stability only in BRAF, but not
NRAS, mutant cells (Supplemental Fig. S1E), coinciding
with its effect on their growth. Furthermore, Ino80 overex-
pression enhancedmelanomacell growth and clonogenec-
ity in both the absence and presence of the inhibitors (Fig.
1F,G) without activating the MAPK pathway (Fig. 1H). Fi-
nally, gene set enrichment analysis (GSEA) showed that
genes down-regulated after vemurafenib treatment were
highly enriched for those that were down-regulated after
Ino80 silencing (Fig. 1I). Together, these results support
the notion that Ino80 may be a critical downstream effec-
tor of the driver kinases during melanoma tumorigenesis
and development.
Ino80 is required for melanoma growth
To test whether INO80 is directly required for melanoma
development, we silenced Ino80 with lentiviral-based
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shRNAs in melanoma cell lines (Supplemental Fig. S2A,
B). We found that Ino80 silencing resulted in a significant
inhibition of cell growth in both BRAF (A375, SK-MEL-28,
and A2058) and NRAS (SK-MEL-147 and SK-MEL-119)
mutant melanoma cell lines, based on the 3-(4,5-dime-
thylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
assay (Fig. 2A). In contrast, growth of primary melano-
cytes was not strongly affected (Supplemental Fig. S2C).
Furthermore, Ino80 depletion dramatically inhibited
both clonogenesis and anchorage-independent growth in
all tested melanoma cell lines, as judged by colony forma-
tion and soft agar assays (Fig. 2B–E). The residual clones
formed from Ino80 shRNA virus transduced cells show
no Ino80 silencing (Supplemental Fig. S3A,B), suggesting
Figure 1. Ino80 is required for melanoma growth in vitro. (A) Western blot showing the protein level of Ino80 inmelanoma cell lines and
primarymelanocytes. β-Actinwas used as the loading control. (B,C ) Western blot showing Ino80 expression after drug treatment. (B) A375
cells were treated with 0.5 µM vemurafenib or 1 nM trametinib, and cells were harvested at the indicated time points after treatment.
β-Actin was used as the loading control. (C ) RPMI-7951- and NRASQ61K-overexpressing A375 cells were treated with 0.5 µM DMSO or
vemurafenib, and cells were harvested at the indicated time points. Ran was used as the loading control. (D) Ino80 mRNA expression
in A375 cells after treatment with 1 nM trametinib. Relative expression was determined by RT-qPCR, and β-actin was used for normal-
ization. (E) Ino80 protein stability in A375 cells. Cells were treated with 50 µg/mL cycloheximide and harvested at the indicated time
points. Ino80 protein was detected by Western blot. (F–H) Ino80 overexpression promotes melanoma cell growth and clonogenicity.
A375 cells were transduced with lentivirus expressing GFP, Ino80, or NRASQ61K and subjected to 3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide (MTT) (F ) and two-dimensional colony formation assay (G) to determine the impact of Ino80 overexpression.
NRASQ61K overexpression is known to confer resistance to vemurafenib (but not trametinib) and serves as a positive control. (H)
Ino80, ERK, andMEK expression and ERK andMEK phosphorylation were determined byWestern blot. (I ) Gene set enrichment analysis
(GSEA) showing that down-regulated genes after vemurafenib treatment were highly enriched for those that were down-regulated after
Ino80 silencing (see the Materials and Methods for more details).
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that they may originate from those that escaped Ino80 si-
lencing. To minimize the possibility of off-target effects,
we confirmed the above results by two additional shRNAs
in A375 (Supplemental Fig. S3C–F). Together, these re-
sults indicate that INO80 is selectively required for the
maintenance of melanoma cells but not melanocytes in
vitro. To test whether Ino80 can act as an oncogene, we
examined the effect of Ino80 overexpression in melano-
cytes. We found that Ino80 overexpression does not acti-
vate the MAPK pathway (Supplemental Fig. S4A). Its
overexpression alone, at the level that we were able to
achieve, is also not sufficient to drive anchorage-indepen-
dent growth and therebymalignant transformation inme-
lanocytes (Supplemental Fig. S4B). However, we cannot
exclude the possibility that simultaneous overexpression
of multiple INO80 subunits may be required.
We next used a xenograft mouse model to test whether
INO80 is also required for melanoma growth in vivo. We
generatedA375cells (BRAFmutant) stablyexpressing a lu-
ciferase reporter gene to monitor tumor growth in live an-
imals by bioluminescence imaging. We transduced the
cells with either the nontargeting (NT) or Ino80 shRNA
lentivirus and injected the cells subcutaneously into im-
munocompromised SCID-Beige mice. Strikingly, Ino80
silencing almost completely suppressed tumor growth in
vivo, based on bioluminescence imaging (Fig. 3A,B). At
18 d after injection, animals were sacrificed, and the tu-
mors were removed for further analysis. Consistent with
the above results, tumors formed by Ino80 silenced cells
were much smaller in size compared with those formed
from NT shRNA transduced cells (Supplemental Fig.
S5A–C) and likely originated from cells that escaped
Ino80 silencing, as Ino80 expressionwas not reduced (Sup-
plemental Fig. S5D). As our results suggested that INO80
may be a critical downstream effector of key driver muta-
tions duringmelanoma tumorigenesis (Fig. 1B–F), we test-
ed whether INO80 is also important for NRAS mutant
melanoma development. Similar to what we observed in
BRAF mutant cells, Ino80 silencing by multiple shRNAs
suppressed xenograft tumor growth in the NRAS mutant
Figure 2. Ino80 silencing significantly inhibits melanoma growth in vitro. (A) Growth curves showing the impact of Ino80 silencing on
melanoma cell lines. Melanoma cells were transduced with lentiviral-based nontargeting (NT) shRNA (shNT) or Ino80 shRNA (shIno80)
and plated on day 1. Cell number (represented by fold change in absorbance) at the indicated time points was determined by MTT assay
and normalized to that of day 1. Data were plotted as mean ± SEM from three independent experiments. (B) Representative images of the
clonogenesis assay inmelanoma cells transduced with NT shRNA or Ino80 shRNAvirus. (C ) Representative images showing anchorage-
independent growth of melanoma cells transduced with NT shRNA or Ino80 shRNA virus. (D,E) Statistical analysis of the anchorage-in-
dependent growth assay showing changes in colony number (D) and colony size (E) of cells transduced with Ino80 shRNA relative to
NT shRNA control.
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cell line SK-MEL-147 (Supplemental Fig. S6). Together
with the observation that Ino80 expression is reduced by
BRAF and MEK inhibitors (Fig. 1B), these results strongly
suggest that INO80 plays a pivotal role in melanoma
growth driven by driver mutations in theMAPK pathway.
Taking it a step further, we next tested whether Ino80
inhibition can inhibit the growth of established tumors.
We transduced A375 melanoma cells with lentivirus ex-
pressing doxycycline (Dox)-inducible NT shRNAs or
Ino80 shRNAs (Fig. 3C) and transplanted the cells
subcutaneously into immune-compromised mice. Tu-
mors were allowed to grow for 12 d to a similar size in
both the NT shRNA and Ino80 shRNA groups, after
which Dox was administered to the animals to induce
the expression of shRNAs. Strikingly, Ino80 silencing
strongly inhibited the growth of established tumors, based
on bioluminescence imaging (Fig. 3D,E). Consistently, the
tumor size and mass in the Ino80 shRNA group were sig-
nificantly smaller than those in the NT shRNA group at
the end of the experiment (Fig. 3F–H). Taken together,
the above data strongly suggest that INO80 is required
for melanoma growth both in vitro and in vivo.
Ino80 regulates the expression of cancer-related genes
To understand how INO80 regulates melanoma growth
at the molecular level, we determined gene expression
changes upon Ino80 silencing at multiple time points in
Figure 3. Ino80 silencing significantly inhibits melanoma growth in mouse xenografts. (A) Representative bioluminescence images
showing inhibition of tumor formation in mouse xenografts after Ino80 silencing. A375 cells were transduced with either NT shRNA
or Ino80 shRNA lentivirus and injected subcutaneously into immunocompromised mice. Tumor cell growth was monitored by biolumi-
nescence imaging at the indicated time points. (B) Statistical analysis of A. Data were plotted as mean ± SEM, where n = 8 in each group.
(C ) Western blot showing efficient Ino80 silencing by doxycycline (Dox)-inducible shRNA. A375 cells were transduced with NT shRNA
or Ino80 shRNA lentivirus, drug-selected, and treated with Dox at 1 µg/mL for 3 d. β-Actin was used as the loading control. (D) Represen-
tative bioluminescence images showing the impact of Ino80 silencing on melanoma growth in mouse xenografts. A375 cells were trans-
duced with lentivirus carrying inducible NT shRNA (Ind-shNT) or Ino80 shRNA (Ind-shIno80). Cells were transplanted to SCID-Beige
mice subcutaneously, and Dox was administered 12 d after transplantation to induce shRNA expression. Tumor growth was monitored
by bioluminescence imaging at the indicated time points. (E) Statistical analysis of tumor bioluminescence. Valueswere plotted asmean ±
SEM, where n = 10 in each group. (F ) Representative images showing the size of tumors dissected at the end of the experiment in Figure
2D. (G,H) Analysis of dissected tumor size (G) and mass (H). Data were plotted as mean ± SEM, where n = 10 in each group.
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A375 by total RNA sequencing (RNA-seq). We found that
nearly two-thirds of differentially expressed genes (DEGs)
were down-regulated upon Ino80 silencing (Fig. 4A), in-
cluding many known to play important roles in
melanoma such as AXL, ERBB3, EPHA2, and SPARC
(Fig. 4B). Consistently, Ingenuity Pathway Analysis (IPA)
showed that the down-regulated genes are heavily en-
riched for those involved in cancer (Fig. 4C). Thus,
INO80 is important foroncogeneexpression inmelanoma.
Interestingly, Ingenuity Upstream Regulator Analysis
Figure 4. INO80 regulates genes important for melanoma progression. (A) Heat map showing gene expression changes upon Ino80
knockdown in A375 cells at the indicated time points. DEGs were defined as those with a fold change of >1.5 and a false discovery
rate (FDR) of <0.05, and the total number of DEGs on days 2, 3, and 4 were 1028, 1956, and 2116, respectively. (B) RT-qPCR showing
down-regulation of genes important inmelanoma after Ino80 silencing. Gene expressionwas normalized to β-actin, and values are plotted
as mean ± SEM from three independent experiments. (C ) IPA showing the enrichment of cancer-related genes in the DEGs upon Ino80
silencing at day 2, 3, or 4. (D) Heat map showing the upstream regulators responsible for the DEGs upon Ino80 knockdown as predicted
by IPA. (E) Heat map showing the biological consequences or associated diseases downstream from the DEGs upon Ino80 knockdown as
predicted by IPA. (F ) Genome browser tracks showing Ino80 occupancy near selectedmelanoma genes AXL, ERBB3, EPHA2, and SPARC
in A375 cells. (G) Venn diagram showing the overlap between DEGs after Ino80 knockdown on day 2 and Ino80-bound genes. (H) GSEA
showing that the 532 INO80 targets were enriched for genes that are highly expressed inmelanoma versus melanocytes. (I ) IPA of the 532
Ino80 target genes. Selected top categories are shown.
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suggested that the gene expression changes caused by
Ino80 silencing were similar to those caused by down-
regulation of signaling pathways highly related tomelano-
ma tumorigenesis, such as ERK1/2, AKT1, and MAP3K8
(Fig. 4D). In addition, the Ingenuity Predicted Biological
Consequences showed that the gene expression changes
caused by Ino80 silencing were consistent with decreased
tumor-related behaviors, including tumor cell proli-
feration, migration, and invasion (Fig. 4E). Collectively,
these analyses suggest that INO80 plays a central role
in the expression of genes important for melanoma
progression.
To identify genes directly regulated by INO80, we car-
ried out ChIP-seq against Ino80 in A375 melanoma cells.
We identified 33,687 Ino80 peaks with high confidence
(false discovery rate [FDR] of <10−6), which can be assigned
to the 8662 nearest genes. Representative genome tracks
showed that Ino80 occupies genomic regions associated
with genes critical for melanoma development, including
AXL, ERBB3, EPHA2, and SPARC (Fig. 4F). Globally,
Ino80-occupied genes were significantly enriched in
those that are highly expressed inmelanoma (Supplemen-
tal Fig. S7A). Of the 1028 DEGs immediately down-regu-
lated after Ino80 silencing, 532 show Ino80 occupancy in
the vicinity and are likely direct targets of INO80 (Fig.
4G). Again, these INO80 targets were significantly en-
riched for genes that are highly expressed in melanoma
compared with normal melanocytes (Fig. 4H) and were
also enriched for genes involved in cancer development
(Fig. 4I). Therefore, these data support the notion that
INO80 may directly regulate oncogenic gene expression
in melanoma cells.
Ino80 regulates oncogenic SEs
To further understand how INO80 regulates genes in-
volved in melanoma tumorigenesis, we examined the
genomic localization of Ino80 peaks and compared Ino80
localization with transcriptional regulatory sequences
such as promoters and enhancers. We found that Ino80
mainly localized near intergenic regions (Fig. 5A). Fur-
thermore, Ino80 occupancy significantly overlapped
and positively correlated with enhancer and SE mar-
kers H3K4me1, H3K27ac, and Med1 in both BRAF and
NRAS mutant cells (Fig. 5B,C). These results are consis-
tent with the idea that INO80 occupies enhancers in
melanoma cells. Importantly, Ino80, H3K27ac, and Med1
colocalized at enhancer regions associatedwith oncogenic
genes such asBCL91 andAXL. Furthermore, this colocali-
zation was observed in only melanoma cells but not pri-
mary melanocytes (Fig. 5D), suggesting that dynamic
Ino80 occupancy at enhancers may contribute to the dif-
ferential expression of oncogenes in melanoma. As chro-
matin remodelers can often be recruited by transcription
factors (Iwafuchi-Doi and Zaret 2014; Laurette et al.
2015), we examined whether Ino80 occupancy is depen-
dent on transcription factors involved inmelanoma devel-
opment, such as MITF and Sox9. Indeed, we found that
Ino80 genomic occupancy was impaired upon MITF or
Sox9 silencing (Fig. 5E–H), suggesting that the transcrip-
tion factors may facilitate the recruitment of INO80 to
regions near melanoma-related genes.
Intriguingly, Ino80 occupancy strongly correlated with
that of the SE markers Med1 and H3K27ac (Fig. 5B,C).
In addition, Ino80-bound regions displayed higher signals
for Med1 and H3K27ac compared with Ino80-unbound re-
gions (Fig. 6A; Supplemental Fig. S7B). Thus, we set out
to test the hypothesis that INO80may regulate oncogenic
SEs. We used the Med1 ChIP-seq to define SEs in melano-
ma cells. This definition resulted in a total of 1084 SEs
associated with 473 genes. These SE-associated genes
includemanywell-characterized genes important formel-
anoma development such as SOX10 and AXL (Supple-
mental Fig. S7C) and are highly enriched for genes
involved in cancer proliferation and invasion (Sup-
plemental Fig. S7D). Notably, ∼90% (422 out of 473) SE-
associated genes were occupied by Ino80 (Fig. 6B). More-
over, SE-associated genes, but not regular enhancer (RE)-
associated-genes, were down-regulated upon Ino80 silenc-
ing (Fig. 6C; Supplemental Fig. S7E). Consistently, GSEA
showed that SE genes were significantly enriched in
Ino80 knockdown-repressed genes (Fig. 6D). Collectively,
these results support themodel that INO80 directly occu-
pies SEs to promote the expression of oncogenic genes in
melanoma.
As INO80 is a chromatin remodeler and can regulate
nucleosome occupancy and turnover, we hypothesized
that INO80 may regulate oncogenic SEs via the action
of chromatin remodeling. To test this, we determined
nucleosome occupancy in melanoma cells before and af-
ter Ino80 depletion using the recently developed assay
for transposase-accessible chromatin (ATAC) with high-
throughput sequencing (ATAC-seq) (Buenrostro et al.
2015). We found that Ino80 silencing led to significant in-
creases in nucleosome occupancy at Ino80-bound regions
(Fig. 7A,B), suggesting that INO80may normally promote
nucleosome depletion. Interestingly, Ino80-dependent
nucleosome depletion occurs at both SE- and RE-associat-
ed genes (Supplemental Fig. S7F,G). To test how INO80-
mediated chromatin remodeling affects SE function, we
examined the impact of Ino80 depletion on the occupancy
of Med1, a component of the Mediator complex and a
commonly used SE marker. Indeed, Med1 occupancy at
SEs was significantly compromised upon Ino80 silencing
(Fig. 7C). In contrast, Med1 occupancy at REs was not af-
fected (Fig. 7D,E). This result is consistent with the obser-
vation that Ino80 silencing resulted in the down-
regulation of SE-associated, but not RE-associated, genes
(Fig. 6C; Supplemental Fig. S7E). Because SEs are bound
by an unusually high density of transcription factors
and enhancer markers, it is possible that they are more
sensitive to changes in the chromatin state. Together,
these results support the model that INO80 promotes on-
cogene transcription by regulating nucleosome occupan-
cy and the assembly of oncogenic SEs in melanoma cells
(Supplemental Fig. S8).
Finally, we asked whether INO80 occupancy can be
used to improve the current definition of SEs. Instead
of using all Med1 peaks, we redefined SEs using only
Med1 peaks that were co-occupied by Ino80. We found
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that this new definition produced a list of SEs that were
better associated with genes selectively expressed in
melanomas compared with melanocytes (Fig. 7F). This
result suggested that INO80 may be an integral compo-
nent of SEs. Collectively, our results reveal a critical
role of the INO80 chromatin remodeling complex in
the determination of cell type-specific gene expression
in cancer.
Discussion
SEs play critical roles in driving the expression of cell
identity genes (Hnisz et al. 2013; Loven et al. 2013; Whyte
et al. 2013; Chipumuro et al. 2014). Therefore, uncovering
key factors that dictate the dynamic regulation of SEs will
provide effective ways to manipulate cell fates during de-
velopment and disease. In this study, we identified INO80
Figure 5. Ino80 occupies genomic regions near melanoma-related genes. (A) Ino80 peak distribution in the genome. (B,C ) Heat maps
showing Ino80, Med1, H3K27ac, and H3K4me1 occupancy in the BRAF mutant A375 cells (B) or NRAS mutant SK-MEL-147 cells (C ).
Genes were sorted based on the Ino80 signal around the Ino80 peak center. (D) Genome browser showing Ino80, Med1, and H3K27ac oc-
cupancy near representative SE genes in A375 and SK-MEL-147melanoma cells and in primary melanocytes. (E–H) Dependency of Ino80
occupancy on MITF and Sox9. MITF or Sox9 was silenced by lentiviral shRNAs in A375 cells (E,G), and the Ino80 occupancy at selected
genes was determined by ChIP-qPCR (F,H).
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as a novel and important component of SEs. Using INO80
and Med1 occupancy, we defined the SEs in melanoma
cells. Compared with SEs defined based on Med1 occu-
pancy alone, those co-occupied by INO80 and Med1 are
better enriched for genes specifically expressed in mela-
noma and may provide new insights into melanoma tu-
morigenesis. More importantly, we showed that INO80-
mediated chromatin remodeling is required for Med1
occupancy and the full activity of SEs in melanoma. Con-
sistent with our findings, SEs have been proposed to be
sensitive to perturbation of chromatin-basedmechanisms
(Pott and Lieb 2015). In addition, nucleosome positioning
and chromatin remodeling are known to influence the ac-
tivity of REs (Hu et al. 2011; Laurette et al. 2015), and nu-
cleosome occupancy changes over key regulatory regions
during cell fate transition (West et al. 2014). Thus, our
data reveal a critical role of chromatin remodeling in
the assembly and function of SEs and identify INO80 as
a potential target for the regulation of cell type-specific
gene expression in disease and development. It is worth
noting that Ino80 depletion was previously reported to in-
hibit proliferation and anchorage-independent growth of
oncogene transformed mouse embryonic fibroblasts.
However, INO80 haploinsufficiency had no impact on tu-
mor incidence and latency in p53 deletion mice (Min
et al. 2013). It is possible that there may still be a suffi-
cient amount of Ino80 in the heterozygote mice to allow
tumorigenesis, and different cancers or different cell
types may show different dependency on the expression
level of Ino80.
In addition to the driver mutations (Hodis et al. 2012;
The Cancer Genome Atlas Network 2015), recent studies
havebegun to reveal the roles of epigeneticmechanisms in
the regulation of oncogene expression, tumorigenesis, and
tumor maintenance (Lee et al. 2014). For example, muta-
tions in the SWI/SNF chromatin remodeling complex
were found to be prevalent in many cancers, and the com-
plex itself was suggested to function as a tumor suppressor
(Gonzalez-Perez et al. 2013; Shain and Pollack 2013). In
both melanocytes and melanoma, the SWI/SNF complex
interacts with master transcription factors and promotes
cell differentiation and survival (Mehrotra et al. 2014). In
comparison, we showed that INO80 silencing reduces on-
cogenic transcription and selectively inhibits the growth
of both BRAF and NRAS mutant melanoma cells but not
primary melanocytes. Thus, our study provides a novel
and potentially promising strategy to inhibit cancer pro-
gression by targeting the INO80 chromatin remodeling
complex,whichmaycomplement andovercomechalleng-
es in existing targeted therapies (Marzuka et al. 2015).
Finally, we found that INO80 selectively occupies on-
cogenic SEs in melanoma cells but not primary melano-
cytes, suggesting that chromatin remodeling may act as
a critical step during the establishment of oncogenic SEs
during tumorigenesis. In addition, our data showed that
driver kinase inhibition reduced Ino80 expression. At
the same time, Ino80 silencing impairs BRAF and NRAS
mutant cell growth and tumorigenesis. Thus, the driver
kinases may hijack INO80 as a means to establish onco-
genic SEs and promote tumor formation. Consistent
with this notion, a recent report showed that SEs provide
a platform for signaling pathways to regulate genes that
control cell identity during tumorigenesis (Hnisz et al.
2015). We propose that INO80 may play an important
role in bridging upstream signaling pathways and the tran-
scriptional activation of oncogenes.
Figure 6. Ino80 occupies oncogenic SE genes and promotes their expression. (A) Average ChIP-seq read density of Med1, H3K27ac, and
H3K4me1 at Ino80-bound and Ino80-unbound genes. (B) Venn diagram showing the overlap between Ino80-bound and SE genes. (C ) Box
plots showing gene expression changes for all genes (ALL) versus SE genes upon Ino80 silencing in A375 cells at the indicated time points.
The P-values were calculated by Student’s t-test. (D) GSEA showing that SE genes were preferentially enriched for those that are down-
regulated after Ino80 silencing.
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Materials and methods
Cell lines
Human melanoma cells (A375, SK-MEL-28, A2058, SK-MEL-147,
and SK-MEL-119) were purchased from the TissueCulture Facility
at the University of North Carolina at Chapel Hill. All cells were
maintained in Dulbecco’s modified Eagle’s medium (DMEM) sup-
plementedwith 10%FBS and 1%penicillin/streptomycin (Invitro-
gen). Humanmelanocytes were purchased from Life Technologies
andmaintainedinMedium254withtheadditionofhumanmelano-
cyte growth supplement (HMGS) (Life Technologies).
Antibodies
The following antibodies were used in this study: Ino80 (Protein-
tech, 24819-1-AP) and β-actin (Sigma, A2228) for Western
blotting; Ino80 (Proteintech, 18810-1-AP) for immunohistochem-
istry staining; and Ino80 (Proteintech, 18810-1-AP), H3K4me1
(Active Motif, 39297), H3K27ac (Abcam, ab4729), Med1 (Bethyl
Laboratories, A300-793A), and RNA Pol II (Santa Cruz Biotech-
nology, SC-899X) for ChIP.
Human samples
Approval for this study was obtained from the ethics committee
of Wuhan University. All study samples were obtained from pa-
tients between 2009 and 2014 who were treated at Renmin Hos-
pital of Wuhan University (Wuhan, China), with written
informed consent from the patients. Two pathologists (J.P.
Yuan and Y.B. Huang) reconfirmed the histopathological features
of these samples.
Figure 7. INO80 regulates nucleosome occupancy andMediator recruitment at oncogenic SEs. (A) Genome tracks showing nucleosome
occupancy at SEs nearmelanoma-related genes inNT versus Ino80 knockdownA375 cells. (B) AverageATAC-seq nucleosome-associated
readdensityat Ino80-boundregionsinNTversus Ino80knockdownA375cells.TheP-valueswerecalculatedbyStudent’st-test. (C )Genome
browser tracks showingMed1 andPol II occupancyat SEs near selectedmelanoma-related genes inNTor Ino80knockdownA375 cells. (D)
AverageChIP-seqreaddensityofMed1aroundtheMed1peakcenteronSEsversusREs inNTor Ino80knockdownA375cells. (E) Boxplotof
Med1ChIP-seqreaddensityonSEsversusREsinNTorIno80knockdownA375cells. (F )GSEAofSE-associatedgenesingenesthatarehighly
expressed inmelanoma compared withmelanocytes. SEs are defined byMed1 occupancy alone orMed1 and Ino80 co-occupancy.
INO80 in melanoma and superenhancer activation
GENES & DEVELOPMENT 1449
Immunohistochemistry staining
Paraffin-embedded human melanoma or nevus samples were
immunostained using standard protocols. Sections were incubat-
ed with anti-Ino80 antibody (1:100; Proteintech, 18810-1-AP),
horseradish peroxidase-conjugated goat anti-rabbit IgG, and 3,3-
diaminobenzidine successively. Afterward, sections were coun-
terstained with hematoxylin. Representative images from six
melanoma samples and three nevus samples are shown.
Western blotting
Cells were lysed in cell lysis buffer (Thermo Scientific) containing
1× protease inhibitor tablet (Roche). The lysates were subse-
quently sonicated and quantified by BCA assay (Life Technolo-
gies). Forty micrograms of proteins was loaded and separated by
SDS-PAGEon 4%–12%Bis-Tris gel (Life Technologies) and trans-
ferred to nitrocellulose membranes. The membranes were
blocked by 5% milk in TBS-T and then incubated with primary
antibodies overnight at 4°C. Afterward, membranes were incu-
bated with the appropriate secondary antibodies and developed
using the ECL detection kit (GE Healthcare Bio-Sciences).
RNA isolation, reverse transcription, and RT-qPCR
Total RNA was isolated from cells using the GeneJet RNA puri-
fication kit (Thermo Scientific), and 0.5 µg of total RNA was re-
verse-transcribed to generate cDNA using the iScript cDNA
synthesis kit (Bio-Rad) according to the manufacturer’s instruc-
tions. qPCRwas performed using the SsoFast EvaGreen supermix
(Bio-Rad) on the Bio-Rad CFX-384 or CFX-96 real-time PCR
detection system. Actin was used for normalization. Primers
used in the study are listed in Supplemental Table S1.
Cell proliferation assay
Standard MTT proliferation assays were performed. Cells were
plated at the appropriate densities (1 × 103 to 2 × 103 cells per
well) in 96-well plates. The next day (day 1), 5 mg/mL MTT/
PBS was added to each well to one-tenth the original culture vol-
ume and incubated for 4 h at 37°C. Medium was carefully re-
moved, and 150 µL of 0.04 N HCl in absolute isopropanol was
added to each well to solubilize the resulting formazan and shak-
en for 15 min at room temperature. Data were collected with
a Synergy 2 multimode plate reader (BioTek). The procedures
were repeated on days 3, 5, and 7. Datawere normalized to the av-
erage value of day 1, and growth curves were generated from the
average of all experiments.
Clonogenic assay
Cells were plated in triplicate at the appropriate cell densities for
each cell line (100–500 cells per well) in six-well plates and cul-
tured for 2–4 wk for colony formation. Resulting colonies were
washed once with PBS, fixed, and stained with 0.05% (w/v) crys-
tal violet in 50% methanol and 10% acetic acid for 30 min at
room temperature. Colonies were carefully rinsed with distilled
water until background staining of the wells was minimal. Plates
were air-dried and scanned. Staining intensities were quantified
with ImageJ (version 1.45s).
Soft agar assay
Cells were resuspended in 0.4% agar in complete medium at
1 × 104 cells per well in six-well plates and layered on top of
0.6% agar as described previously (Shutes et al. 2004). After 14
d, colonies were stained with 2 mg/mL MTT dissolved in PBS
for 1 h at 37°C. Plates were scanned, and colonies were quanti-
fied with ImageJ.
Mouse xenograft experiments
All animal experiments were conducted following protocols ap-
proved by the Institutional Animal Care and Use Committee of
the National Institute of Environmental Health Sciences. A375
cells or SK-MEL-147 cells (2 × 106 cells) carrying a luciferase re-
porter plasmid (Promega) with either lentiviral-based NT shRNA
or Ino80 shRNAwere injected subcutaneously into the flanks of
8- to 10-wk-old SCID-Beigemice (Charles River Laboratories). For
experiments with preformed tumors, A375 cells transduced with
either inducible NT shRNA or inducible Ino80 shRNA lentivirus
were injected subcutaneously into the flanks of SCID-Beigemice,
and cells were allowed to grow for 12 d to form tumors. After that,
2mg/mLDoxwas administered orally in the drinkingwater to in-
duce the expression of corresponding shRNAs. For biolumines-
cence imaging experiments, 15 mg/mL D-luciferin (Caliper
LifeSciences) was injected intraperitoneally based on 10 µL per
gram of body weight. At 10–15 min after injection, luciferase sig-
nal was detected by a Xenogen IVIS imaging system (STTARR).
Mice were sacrificed at the indicated time points, and tumor
mass and size were measured. Tumor size was calculated based
on a formula described previously (Tomayko and Reynolds 1989).
RNA-seq
A375 cells were transducedwithNT (NT shRNA) or Ino80 (Ino80
shRNA) lentiviral-based shRNAs. Total RNAwas extracted from
cells using the GeneJet RNA purification kit (Thermo Scientific).
One microgram of RNA was used for sequencing library genera-
tion using the TruSeq RNA library preparation kit version 2 (Illu-
mina) according to the manufacturer’s instructions. All libraries
were sequenced on the NextSeq sequencer (Illumina) using the
75-nucleotide (nt) paired-end sequencing protocol.
ChIP-seq
Ino80,H3K4me1, H3K27ac,Med1, andRNAPol II ChIPwere per-
formed as described previously (Whyte et al. 2013). Briefly, A375
or SK-MEL-147 cells were fixed using 1% formaldehyde for
10 min, and 0.125M glycine was added to stop the fixation. Cells
were harvested, and DNA was fragmented to 300–500 base pairs
(bp) by sonicationwith amicrotip attached to aMisonix 3000 son-
icator. Immunoprecipitation was performed with antibodies con-
jugated to Dynabeads protein G beads (Life Technology). ChIP
DNAwas eluted, reverse-cross-linked, extracted by phenol/chlo-
roform, and precipitated.
For theMed1 and Pol II ChIP in Figure 4, A375 cells were trans-
duced with NT shRNA or Ino80 shRNA viruses. After 48 h, cells
were harvested for ChIP against Med1 or Pol II, based on the pro-
cedure described above. For ChIP-seq, 1 ng of ChIP DNA or input
DNAwas used to generate sequencing libraries using theNextera
XT DNA sample preparation kit (Illumina). Libraries were se-
quenced on the NextSeq sequencer (Illumina) using the 75-nt
paired-end sequencing protocol. Two biological replicates were
performed for each ChIP-seq sample, and reads were combined
for analysis.
ATAC-seq
ATAC-seq (Buenrostro et al. 2015)was performedwith amodified
protocol. Briefly, A375 cells were transduced with lentiviral
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shRNAs. At 48 h after transduction, 80,000 cells were harvested
and washed twice with cold PBS. Cells were lysed with 25 µL of
CSK buffer (10 mM PIPES at pH 6.8, 100 mM NaCl, 300 mM
sucrose, 3 mMMgCl2, 0.1%Triton X-100) for 5min on ice. After
lysis, cell nuclei were spun down, and 25 µL of transposase solu-
tion (12.5 µL of 2× TD buffer, 5 µL of Tn5 transposase, 7.5 µL of
nuclease free water) was added. Transposition reactions were in-
cubated for 30 min at 37°C. After incubation, DNA was purified
with the MinElute PCR purification kit (Qiagen) and sub-
sequently amplified by PCR. The PCR reaction was set up as fol-
lows: 10 µL of elutedDNA, 2.5 µL of 25 µM index primer 1, 2.5 µL
of 25 µM index primer 2, 25 µL of New England Biolabs 2× PCR
master mix, and 5 µL of nuclease-free water. PCR was run with
a 12-cycle program (5 min at 72°C, 30 sec at 98°C, 10 sec at 98°
C, 30 sec at 63°C, and 1 min at 72°C; repeat steps 2–5 for another
11 cycles). The quality of amplified DNAwas examined on a Bio-
analyzer, and the DNA was subsequently sequenced on a Next-
Seq sequencer by 75-nt paired-end sequencing.
RNA-seq data analysis
Raw reads were filtered to include only those with a median
Phred quality score of ≥20 and trimmed with Galore! version
0.2.8 to remove adapter sequences. The average mate inner dis-
tance and variance of the fragment lengthswere estimated by first
aligning a subset of the reads to the hg19 known gene transcrip-
tome using Bowtie version 0.12.8 with the following parameters:
-v 2 -m 1 -X 1000. Next, the CollectInsertSizeMetrics tool from
Picard tools suite version 1.86 was used to obtain the mean and
variance estimates for the fragment lengths, and the average
mate inner distance was calculated based on the mean fragment
length and the read length. The gene model was defined using
RefGene annotations downloaded from the University of Califor-
nia at Santa Cruz (UCSC) browser on February 5, 2013. The fil-
tered and trimmed reads were aligned to the hg19 genome
assembly using TopHat2 version 2.0.4 with the mate inner dis-
tance, mate standard deviation, and gene model parameters de-
fined from the previous steps and the following additional
parameter: -g 10. The expression was quantified using CuffLinks
version 2.0.2 with the genemodel to obtain FPKM (fragments per
kilobase per million mapped fragments) measurements for each
gene. Only genes with an FPKM value of ≥0.1 in all samples
were kept for downstream analysis.
Public RNA-seq data for seven melanoma cell lines fromGene
Expression Omnibus (GEO; GSE46817) and public RNA-seq data
for one melanocyte cell line from GEO (GSM1138580) were pro-
cessed and aligned, and FPKMvalues were calculated in the same
way as the other RNA-seq data. Genes were filtered to include
only those with an FPKM value of ≥1 in all samples, and quantile
normalizationwas performed. The log2 fold change of the average
of the normalized melanoma FPKM values over the melanocyte
FPKM value was calculated for each gene.
GSEA between vemurafenib treatment and Ino80 silencing
Gene expression data for vemurafenib-treated A375 cells were ob-
tained from GEO (GSE42872). For genes with multiple probes, a
single expression measurement was calculated by taking the
mean across all probes. P-values were calculated for each gene us-
ing a two-sample Student’s t-test, and FDR values were corrected
formultiple comparisons using the Benjamini-Hochbergmethod.
Vemurafenib target genes were defined as those that were down-
regulated upon vemurafenib treatment with a fold change of >1.5
and an FDR of <0.01. Gene expression changes after Ino80 silenc-
ing were determined as described above.
ChIP-seq analysis
Cutadapt version 1.2.1 was used to trim any reads containing an
adapter sequence. The trimmed reads were filtered to include
only thosewith amedianPhred quality score of≥20.The trimmed
and filtered readswerealigned to thehg19 genomeassemblyusing
Bowtie version 0.12.8 with the following parameters: -v 2 -m 1
–best –strata -I 15 -X 1000.We removed duplicate read pairswhere
both mates in a pair aligned to the same genomic positions. Cov-
erage tracksweregenerated fromthe full-lengthaligned fragments
using the genomecov tool from BEDTools suite version 2.16.2.
Thedepths in thecoverage trackswerenormalizedbymultiplying
by 10 million and dividing by the total number of aligned read
pairs. Peakswerecalled andassigned to genesusingSICERversion
1.1 and the following parameters: redundancy_threshold = 100,
window_size = 200, gap_size = 800, species = hg19, effective_ge-
nome_fraction = 0.77, and FDR = 0.00001. Bound genes were de-
fined by finding the TSS closest to each peak center using
RefGene annotations downloaded from the UCSC browser on
February 5, 2013, and only those whose peak center was within
20 kb of the TSSwere included. Heat mapswere generated by cal-
culating the average normalized depth in 50-nt bins that span 5 kb
upstream of and downstream from the peak centers. Metagenes
were generated by averaging each 50-nt bin across all peaks. Box
plots were generated using the average depth within the entire
window5 kb upstream of and downstream fromeach peak center.
This average depth for each peak was used to calculate a P-value
between two groups using a two-sample Student’s t-test.
ATAC-seq analysis
Cutadapt version 1.2.1 was used to trim any reads containing an
adapter sequence. The trimmed reads were filtered to include
only thosewith amedianPhred quality score of≥20.The trimmed
and filtered readswerealigned to thehg19 genomeassemblyusing
Bowtie version 0.12.8 with the following parameters: -v 2 -m 1
–best –strata -I 15 -X 1000.We removed duplicate read pairswhere
bothmates in a pair aligned to the same genomic position. To ad-
just the fragments to represent the center of the transposon-bind-
ing event, all reads aligning to the plus strandwere offset by +4 nt,
and those aligning to the minus strand were offset by −5 nt. Read
pairs were split into two groups based on fragment length: Those
<100 nt were defined as open chromatin, and those between 180
and 247 nt were defined as mononucleosome. Coverage tracks
were generated for both groups from the full-length aligned frag-
ments using the genomecov tool from BEDTools suite version
2.16.2. The depth in the coverage tracks were normalized bymul-
tiplying by 10million and dividing by the total number of aligned
read pairs in each group. Further normalization of the nucleosome
group was carried out by subtracting the normalized open chro-
matin signal from it. Metagenes and P-values were calculated in
the same way as for the ChIP-seq data.
SE definition
The Med1 ChIP-seq data were used to identify SEs based on the
method described previously (Whyte et al. 2013). Briefly, a rank
was assigned to each of the Med1 peaks based on their SICER
FDR values. Next, a plot with rank on the X-axis and −log10(FDR
value) on the Y-axis was created, normalizing the plot such that
each axis ranged between 0 and 1. Finally, the point in the curve
where the slope transitioned to >1 was identified. All of the peaks
that fell beyond this transition point were defined as SEs. SE-asso-
ciated genes were defined by finding the TSSs closest to each SE
center, only including those whose center was within 20 kb of
the TSS.
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Accession numbers
The GEO accession number for the data reported in this study is
GSE 82334.
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